文献速递精神分裂症与精神病性障碍

精神分裂症谱系障碍首次精神病发作后20年阳性与阴性症状轨迹:OPUS研究结果

20-year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS study.
PubMed 文献 · World Psychiatry · 2023-01-01

基于OPUS试验373名ICD-10精神分裂症谱系障碍患者,在基线及1、2、5、10、20年评估阳性和阴性症状,用潜在类别增长混合模型识别轨迹。阳性症状呈5种轨迹,早期持续缓解占50.9%;阴性症状呈2种轨迹,持续症状占49.0%。未治疗精神病病程长和合并物质使用障碍是可干预的不良轨迹预测因素。

要点

  • 阳性症状5种轨迹,早期持续缓解占50.9%,持续严重症状占9.1%。
  • 阴性症状2种轨迹,持续症状占49.0%,男性及未治疗精神病病程长是预测因素。
  • 持续阳性或阴性症状与较低神经认知及20年随访时较高抗精神病药使用相关。

核心结论

  • 多数首发精神分裂症谱系障碍患者阳性症状呈早期稳定缓解轨迹。
  • 约半数患者阴性症状随时间不改善。
  • 未治疗精神病病程长和合并物质滥用是可干预的阳性症状不良轨迹预测因素。

研究设计与样本

  • OPUS试验纳入373名ICD-10精神分裂症谱系障碍患者。
  • 基线及1、2、5、10、20年用阳性和阴性症状量表评估。
  • 采用潜在类别增长混合模型识别轨迹,多项回归分析探讨轨迹预测因素。

主要发现

  • 阳性症状5种轨迹:早期持续缓解50.9%、稳定改善18.0%、间歇症状10.2%、复发伴中度症状11.9%、持续严重症状9.1%。
  • 阴性症状2种轨迹:症状缓解51.0%、持续症状49.0%。
  • 持续阳性症状轨迹与BACS z评分-0.78(CI:-1.39至-0.17)相关。
  • 持续阴性症状轨迹与BACS z评分-0.33(CI:-0.53至-0.13)相关。
  • 20年随访时持续阳性症状轨迹抗精神病药使用78%,持续阴性症状轨迹67%。

关键数值与推荐

  • 物质使用障碍预测复发伴中度症状轨迹(OR:2.83,95% CI:1.09-7.38,p=0.033)。
  • 未治疗精神病病程长预测复发伴中度症状轨迹(OR:1.02,95% CI:1.00-1.03,p=0.007)。
  • 较高阴性症状水平预测复发伴中度症状轨迹(OR:1.60,95% CI:1.07-2.39,p=0.021)。
  • 未治疗精神病病程长预测持续严重症状轨迹(OR:1.01,95% CI:1.00-1.02,p=0.030)。
  • 男性预测持续阴性症状轨迹(OR:3.03,95% CI:1.48-6.02,p=0.002);未治疗精神病病程长亦为预测因素(OR:1.01,95% CI:1.00-1.02,p=0.034)。

临床怎么用

  • 应重视缩短未治疗精神病病程以改善阳性症状长期轨迹。
  • 对合并物质使用障碍的首发患者需加强干预以降低复发风险。
  • 男性及未治疗病程长的患者需关注阴性症状持续不缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to identify the 20-year trajectories of positive and negative symptoms after the first psychotic episode in a sample of patients with an ICD-10 diagnosis of schizophrenia spectrum disorder, and to investigate the baseline characteristics and long-term outcomes associated with these trajectories. A total of 373 participants in the OPUS trial were included in the study. Symptoms were assessed at baseline and after 1, 2, 5, 10 and 20 years using the Scales for the Assessment of Positive and Negative Symptoms. We used latent class growth mixture modelling to identify trajectories, and multinominal regression analyses to investigate predictors of membership to identified trajectories. Five trajectories of positive symptoms were identified: early continuous remission (50.9% of the sample), stable improvement (18.0%), intermittent symptoms (10.2%), relapse with moderate symptoms (11.9%), and continuous severe symptoms (9.1%). Substance use disorder (odds ratio, OR: 2.83, 95% CI: 1.09-7.38, p=0.033), longer duration of untreated psychosis (OR: 1.02, 95% CI: 1.00-1.03, p=0.007) and higher level of negative symptoms (OR: 1.60, 95% CI: 1.07-2.39, p=0.021) were predictors of the relapse with moderate symptoms trajectory, while only longer duration of untreated psychosis (OR: 1.01, 95% CI: 1.00-1.02, p=0.030) predicted membership to the continuous severe symptoms trajectory. Two trajectories of negative symptoms were identified: symptom remission (51.0%) and continuous symptoms (49.0%). Predictors of the continuous symptoms trajectory were male sex (OR: 3.03, 95% CI: 1.48-6.02, p=0.002) and longer duration of untreated psychosis (OR: 1.01, 95% CI: 1.00-1.02, p=0.034). Trajectories displaying continuous positive and negative symptoms were linked to lower neurocognition, as measured by the Brief Assessment of Cognition in Schizophrenia (BACS) (z-score: -0.78, CI: -1.39 to -0.17, for continuous positive symptoms; z-score: -0.33, CI: -0.53 to -0.13, for continuous negative symptoms). The same trajectories were also linked to higher use of antipsychotic medication at 20-year follow-up (continuous positive symptoms: 78%; continuous negative symptoms: 67%). These findings suggest that the majority of patients with first-episode schizophrenia spectrum disorder have a trajectory with early stable remission of positive symptoms. Long duration of untreated psychosis and comorbid substance abuse are modifiable predictors of poor trajectories for positive symptoms in these patients. In about half of patients, negative symptoms do not improve over time. These symptoms, in addition to being associated with poor social and neurocognitive functioning, may prevent patients from seeking help.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Starzer M, Hansen HG, Hjorthøj C, et al. 20-year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS study. World Psychiatry. 2023. PMID: 37713547. doi:10.1002/wps.21121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。